AR101 Oral Immunotherapy for Peanut Allergy

RCT in 496 subjects aged 4 to 17 years of age with peanut allergy reported that treatment with AR101 (12% defatted peanut flour) resulted in more subjects able to ingest 600 mg or more of peanut protein, without dose-limiting symptoms vs placebo (67.2% vs 4.0%; P<0.001).

A related editorial discusses these results and notes that the longer-term side effects of sustained consumption of an allergen to which the body has produced IgE antibodies remain unknown.

 

Furthermore, studies in this setting have not established the duration for which allergen tolerance is maintained in the absence of ongoing consumption, suggesting that potentially lifelong, regular consumption may be needed to maintain allergen tolerance.